REMARKS

Claims 1-12 are pending. Claims 5, 7, and 9-11 are cancelled without prejudice or disclaimer. Claims 4, 6, 8, and 12 are amended for clarity. Applicants also amend the specification to correct typographical errors. Therefore, no new matter has been added.

Regarding Amendments to the Specification:

Applicants amend the specification to correct typographical errors, which are supported by the original specification as follows:

Amendments on pages 27 lines 34-35, page 28 lines 28-30, and page 30 line 34, replacing the numbers 65 and 68 by 66 and 69, respectively, are supported by Example 15 at page 27 and Table 2 at pages 36-37.

Amendments to Table 1 on page 31, adding rows containing description for compounds 66 and 69, are supported by Example 15 at pages 27-28 and Table 2 at pages 36-37.

Amendments on page 32 lines 2-3, deleting the number 66 and replacing the number 69 with 70, are supported by the specification page 30, lines 32 to 35 and the above amendments.

Amendments to Table 2 on pages 37-38, replacing the term "3-pentyloxycarbonyloxy" with "3-penty**ny**loxycarbonyloxy" to correct the nomenclature of the compounds 73, 76, and 79, are supported by the structures shown in the corresponding columns describing group "R^1" for each of the compounds 73, 76, and 79.

Regarding Claim Rejections:

Claim Rejection under USC § 101

On page 2 of the office action, the examiner has rejected the claims 5, 9, and 10 and alleged as being directed to non-statutory subject matter. Without acquiescing to the rejections, in order to expedite the prosecution, applicants cancel claims 5, 9, and 10 without prejudice or disclaimer.

Double Patenting Rejection

On page 2 of the Office Action, the examiner has rejected claim 4 as being a duplicate of claims 1-3. In response, applicants amend claim 4 to a composition-claim format and add the phrase "**a suitable additive, emulsifier, excipient, adjuvant, solvent, or a carrier or a combination thereof**", which is supported by the specification (see page 10, line 4 to page 13, line 37). No new matter is introduced.

Withdrawal of the rejection is respectfully requested.

Claim Rejection under USC § 112

On page 3 of the office action, the examiner has rejected claims 4, 7 and 8 on clarity grounds. In response, applicants amend claim 4 to a composition-claim format and add the phrase "**a suitable additive, emulsifier, excipient, adjuvant, solvent, or a carrier or a combination thereof**", which is supported by the specification (see page 10, line 4 to page 13, line 37). Applicants cancel claim 7 without prejudice or disclaimer. Applicants also amend claim 8 to a composition-claim format and a dependent of claim 4.

In view of the above amendments and clear support from the specification, withdrawal of the rejection is earnestly requested.

Claim Rejection under USC § 102

On pages 3 and 4 of the office action, the examiner has rejected claims 7 and 8, and claims 1, 2, 4, 6, 7 and 11, and alleged as being anticipated by Minowa (RN-

192941-99-4P) and Minowa (U.S. Patent No. 5,190,952), respectively. Applicants respectfully disagree with the examiner and traverse the rejection.

Applicants note that in order to reject a claim under 35 USC § 102, the examiner must demonstrate that each and every claim term is contained in a single prior art reference. *See Scripps Clinic & Research Foundation v. Genentech, Inc.*, 18 USPQ2d 1001, 1010 (Fed. Cir. 1991); *Hybritech, Inc. v. Monoclonal Antibodies, Inc.*, 231 USPQ 81, 90 (Fed. Cir. 1986); *see also* MPEP § 2131 (Rev. 2, May 2004). Claim terms are to be given their plain meaning as understood by the person of ordinary skill in the art, particularly given the limitations of the English language. *See* MPEP §§ 707.07(g); 2111.01 (Rev. 2, May 2004). Claims are to be given their broadest reasonable interpretation consistent with applicants' specification. *See In re Zletz*, 13 USPQ2d 1320, 1322 (Fed Cir. 1989) (holding that claims must be interpreted as broadly as their terms reasonably allow); MPEP § 2111(Rev. 2, May 2004).

Not only must the claim terms, as reasonably interpreted, be present, an allegedly anticipatory reference must enable the person of ordinary skill to practice the invention as claimed. Otherwise, the invention cannot be said to have been already within the public's possession, which is required for anticipation. *See Akzo, N.V. v. U.S.I.T.C.*, 1 USPQ2d 1241, 1245 (Fed. Cir. 1986); *In re Brown*, 141 USPQ 245, 249 (CCPA 1964).

Applicants provide the following explanations to assist the Examiner in distinguishing the cited reference:

Minowa (RN-192941-99-4P) discloses a 4-acetoxy-2,3-dimethyl-6-fluoroquinoline, which has a substitution of a fluorine atom only at 6-position, and not at 5- and/or 7- position, unlike the compounds of the instant invention. Minowa also does not describe a quinoline derivative prepared by substitution at any two of the 5-position to 7-position, which provides a compound with an excellent control effect against ectoparasite (see specification, for example, page 1, lines 25-27, and page 42, line 33 to page 46).

Therefore, Minowa (RN-192941-99-4P) does not anticipate the claimed invention.

Regarding Minowa (U.S. Patent No. 5,190,952), applicants indicate that:

(1) Minowa disclosure directs towards the substitution of a fluorine atom only at 6-position, and not at the 5- or 7- positions;

(2) Minowa does not disclose compounds that are effective against ectoparasites (see Minowa, col. 2, lines 53-62, and col. 3, lines 40-56);

(3) The control effect of the claimed quinoline derivatives against ectoparasites (such as *Ctenocephalides felis* and *Dermanyssus gallinae)* is excellent (see specification, for example, page 1, lines 25-27, and page 42, line 33 to page 46) *versus* the compounds of Minowa are not known for their effectiveness against the ectoparasites; and

(4) Minowa does not teach a compound, a composition or a method for controlling ectoparasites of mammals and birds.

Therefore, Minowa does not anticipate the claimed invention.

Applicants further note that the claimed quinoline derivatives have substitutions by halogens atoms or trifluoromethyl groups at any two of the 5-position to 7-position on the quinoline ring (see, for example, definitions of R^3, X, and R^4 in claim 1). The claimed quinoline derivatives have excellent control effect against ectoparasites of mammals and birds. On the other hand, Minowa compounds were prepared by substitution of a fluorine atom or a chlorine atom at 6-position, and were not known to be effective against the ectoparasites such as *Ctenocephalides felis* or *Dermanyssus gallinae*.

Therefore, Minowa can not anticipate the compounds, compositions or the methods, as claimed.

Withdrawal of the anticipation rejection is solicited.

Claim Rejection under USC § 103

On pages 6-7 of the Office Action, the examiner has rejected claims 3, 8, and 12 as allegedly being unpatentable over Minowa (U.S. Patent No. 5,190,952) in view of "the generic teaching" of Minowa.

Applicants respectfully disagree because the examiner has failed to establish a *prima facie* case of obviousness.

To establish a *prima facie* case of obviousness, at least two criteria must be met. First, there must be some motivation or suggestion to make the proposed combination or modification of the references. Further, "the teaching or suggestion to make the claimed combination must be found in the prior art, and not based on the applicant's disclosure." MPEP 2142 (Rev. 2, May 2004), discussing *In re Vaeck*, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir. 1991). In addition, the combined, or modified, references must teach or suggest all claim limitations.

When an examiner alleges a *prima facie* case of obviousness, such an allegation can be overcome by showing that (i) there are elements not contained in the references or within the general skill in the art, (ii) the combination is improper (for example, there is a teaching away or no reasonable expectation of success) and/or (iii) objective indicia of patentability exist (for example, unexpected results). *See U.S. v. Adams*, 383 U.S. 39, 51-52 (1966); *Gillette Co. v. S.C. Johnson & Son, Inc.*, 16 USPQ2d 1923, 1927 (Fed. Cir. 1990); *Bausch & Lomb, Inc. v. Barnes-Hind/Hydrocurve*, 230 USPQ 416, 419-20 (Fed. Cir. 1986). Applicants submit that the rejections do not meet this test.

Applicants provide following arguments to overcome the 35 USC § 103 rejection:

On page 7 of the office action, the examiner agrees that "Minowa does not specifically teach the compounds of claim 3" and discloses a "6-fluoro" compound "verses compound (4) which is a 5,6-difluoro." However, the examiner speculates that one of ordinary skill in the art would make the "5,6-difluoro", although Minowa provides no suggestion or motivation to make the modification. Applicants point out that the Minowa directed towards "6-fluoro" compounds, because, the excellent control effect of the "5,6-difluoro" compounds (see specification, for example, page 1, lines 25-27, and page 42, line 33 to page 46), were not known at the time.

Therefore, the substitutions at any two of the 5-position to 7-position on the quinoline ring provided unexpected results and superior compounds to control ectoparasites.

Applicants also note that even if the Markush group of Minowa encompasses the claimed compounds, which it does not, one skilled in the art would not have any motivation to design a compound with substitutions at the 5-position and/or 7-position on the quinoline ring. Because Minowa directs towards the substitution of a fluorine atom only at 6-position, and not at the 5- or 7- positions. Minowa does not teach compounds that are effective against ectoparasites (see for example, Minowa, col. 2, lines 53-62, and col. 3, lines 40-56). Therefore, Minowa disclosure can not make the claimed invention obvious.

Withdrawal of the obviousness rejection is respectfully requested.

REQUEST RELIEF

In view of above amendments and remarks, applicants respectfully submit that claims 1-4, 6, 8, and 12 are allowable, and respectfully request favorable consideration to that effect. The Examiner is invited to contact the undersigned at (202) 912-2000 should there be any questions.

Respectfully submitted,

April 1, 2005
Date

John P. Isacson
Reg. No. 33,715

Heller Ehrman LLP
1717 Rhode Island Av. NW
Washington, DC 20036-3001
Phone: (202) 912-2000
Fax: (202) 912-2020

Customer No. 26633

Table 1

Compd. No.	Name of compound	R^1	R^2	R^3	R^4	X
1	2-ethyl-3-methyl-4-cyclopropanecarbonyloxy-6,7-difluoroquinoline	c-Pr	Et	H	F	F
2	2-ethyl-3-methyl-4-cyclopropanecarbonyloxy-5,6-difluoroquinoline	c-Pr	Et	F	H	F
3	2-ethyl-3-methyl-4-acetyloxy-6,7-difluoroquinoline	Me	Et	H	F	F
12	2-ethyl-3-methyl-4-acetyloxy-5,6-difluoroquinoline	Me	Et	F	H	F
15	2,3-dimethyl-4-cyclopropanecarbonyloxy-6,7-difluoroquinoline	c-Pr	Me	H	F	F
16	2,3-dimethyl-4-cyclopropanecarbonyloxy-5,6-difluoroquinoline	c-Pr	Me	F	H	F
17	2,3-dimethyl-4-acetyloxy-6,7-difluoro-quinoline	Me	Me	H	F	F
18	2-ethyl-3-methyl-4-acetyloxy-6-fluoro-7-chloroquinoline	Me	Et	H	Cl	F
19	2-ethyl-3-methyl-4-acetyloxy-5-chloro-6-fluoroquinoline	Me	Et	Cl	H	F
20	2-ethyl-3-methyl-4-cyclopropanecarbonyloxy-6-fluoro-7-chloroquinoline	c-Pr	Et	H	Cl	F
21	2-ethyl-3-methyl-4-cyclopropanecarbonyloxy-5-chloro-6-fluoroquinoline	c-Pr	Et	Cl	H	F
22	2-ethyl-3-methyl-4-isopropoxycarbonyloxy-6-fluoro-7-chloroquinoline	O-i-Pr	Et	H	Cl	F
23	2-ethyl-3-methyl-4-isopropoxycarbonyloxy-5-chloro-6-fluoroquinoline	O-i-Pr	Et	Cl	H	F
26	2,3-dimethyl-4-cyclopropanecarbonyloxy-6-fluoro-7-chloroquinoline	c-Pr	Me	H	Cl	F
27	2,3-dimethyl-4-cyclopropanecarbonyloxy-5-chloro-6-fluoroquinoline	c-Pr	Me	Cl	H	F
28	2,3-dimethyl-4-methoxycarbonyloxy-6-fluoro-7-chloroquinoline	O-Me	Me	H	Cl	F
34	2-isopropyl-3-methyl-4-cyclopropane-carbonyloxy-6,7-difluoroquinoline	c-Pr	i-Pr	H	F	F
36	2-ethyl-3-methyl-4-methoxycarbonyloxy-5-chloro-6-fluoroquinoline	O-Me	Et	Cl	H	F
39	2-ethyl-3-methyl-4-methanethiolcarbonyloxy-5,6-difluoroquinoline	S-Me	Et	F	H	F
44	2,3-dimethyl-4-acetoxy-5,6-difluoro-quinoline	Me	Me	F	H	F
53	2,3-dimethyl-4-(3-transchloroacryloyloxy)-5,6-difluoroquinoline		Me	F	H	F
54	2,3-dimethyl-4-(3-cischloroacryloyloxy)-5,6-difluoroquinoline		Me	F	H	F
58	2,3-dimethyl-4-(5-hexynoyloxy)-5,6-difluoroquinoline	4-Pentynyl	Me	F	H	F
61	2,3-dimethyl-4-cyclopropanecarbonyloxy-5-trifluoromethyl-6-fluoroquinoline	c-Pr	Me	CF_3	H	F
63	2,3-dimethyl-4-cyclopropanecarbonyloxy-6-fluoro-7-trifluoromethylquinoline	c-Pr	Me	H	CF_3	F
65	2,3-dimethyl-4-acetoxy-5,6-dichloro-quinoline	Me	Me	Cl	H	Cl
66	**2,3-dimethyl-4-cyclopropanecarbonyloxy-5,6-dichloroquinoline**	**c-Pr**	**Me**	**Cl**	**H**	**Cl**
68	2,3-dimethyl-4-acetoxy-6,7-dichloro-quinoline	Me	Me	H	Cl	Cl
69	**2,3-dimethyl-4-cyclopropanecarbonyloxy-6,7-dichloroquinoline**	**c-Pr**	**Me**	**H**	**Cl**	**Cl**

Table 2

Compd. No.	Name of compound	R^1	R^2	R^3	R^4	X	Production process (Ex. No.)	Starting material 1	Starting material 2		Yield
4	2-ethyl-3-methyl-4-propionyloxy-6,7-difluoroquinoline	Et	Et	H	F	F	2	446mg	propionyl chloride	222m g	209.9m g
5	2-ethyl-3-methyl-4-valeryloxy-6,7-difluoroquinoline	n-C_4H_9	Et	H	F	F	2	446mg	valeryl chloride	289.2m g	204.5m g
6	2-ethyl-3-methyl-4-cyclobutanecarbonyloxy-6,7-difluoroquinoline	c-Bu	Et	H	F	F	2	446mg	cyclobutanecarbonyl chloride	284.4m g	221.6m g
7	2-ethyl-3-methyl-4-isovaleryloxy-6,7-difluoroquinoline	i-Bu	Et	H	F	F	2	446mg	isovaleryl chloride	289.2m g	253.1m g
8	2-ethyl-3-methyl-4-methoxycarbonyloxy-6,7-difluoroquinoline	O-Me	Et	H	F	F	2	446mg	methyl chloroformate	226.8m g	429.4m g
9	2-ethyl-3-methyl-4-ethoxycarbonyloxy-6,7-difluoroquinoline	O-Et	Et	H	F	F	2	446mg	ethyl chloroformate	260.4m g	518.4m g
10	2-ethyl-3-methyl-4-butoxycarbonyloxy-6,7-difluoroquinoline	O-n-Bu	Et	H	F	F	2	446mg	n-butyl chloroformate	327.6m g	568.7m g
11	2-ethyl-3-methyl-4-isopropoxycarbonyloxy-6,7-difluoroquinoline	O-i-Pr	Et	H	F	F	2	446mg	isopropyl chloroformate	294m g	452.3m g
13	2-ethyl-3-methyl-4-butoxycarbonyloxy-5,6-difluoroquinoline	O-n-Bu	Et	F	H	F	3	250mg	n-butyl chloroformate	170mg	328.4m g
14	2-ethyl-3-methyl-4-isopropoxycarbonyloxy-5,6-difluoroquinoline	O-i-Pr	Et	F	H	F	3	250mg	isopropyl chloroformate	200mg	363.2mg
24	2-ethyl-3-methyl-4-methoxycarbonyloxy-5,6-difluoroquinoline	O-Me	Et	F	H	F	3	112mg	methyl chloroformate	100mg	80mg
25	2,3-dimethyl-4-methoxycarbonyl-oxy-5,6-difluoroquinoline	O-Me	Me	F	H	F	12	200mg	methyl chloroformate	150mg	228.9mg
29	2,3-dimethyl-4-acetoxy-6-fluoro-7-chloroquinoline	Me	Me	H	Cl	F	10	100mg	acetyl chloride	100mg	34mg

30	2-ethyl-3-methyl-4-propionyloxy-5,6-difluoroquinoline	Et	Et	F	H	F	3	200mg	propionyl chloride	100mg	202.7mg
31	2-ethyl-3-methyl-4-cyclobutanecarbonyloxy-5,6-difluoroquinoline	c-Bu	Et	F	H	F	3	200mg	cyclobutanecarbonyl chloride	128mg	231mg
32	2-ethyl-3-methyl-4-isobutanecarbonyloxy-5,6-difluoroquinoline	i-Bu	Et	F	H	F	3	200mg	isobutanecarbonyl chloride	128mg	234.8mg
33	2-ethyl-3-methyl-4-ethoxycarbonyl-oxy-5,6-difluoroquinoline	O-Et	Et	F	H	F	3	200mg	ethyl chloroformate	117.2mg	222.9mg
35	2-isopropyl-3-methyl-4-methoxycarbonyloxy-6,7-difluoroquinoline	O-Me	i-Pr	H	F	F	18	50mg	methyl chloroformate	20mg	45.3mg
37	2-ethyl-3-methyl-4-butoxycarbonyloxy-5-chloro-6-fluoroquinoline	O-n-Bu	Et	Cl	H	F	11	200mg	butyl chloroformate	120.5mg	235.7mg
38	2-ethyl-3-methyl-4-ethoxycarbonyloxy-5-chloro-6-fluoroquinoline	O-Et	Et	Cl	H	F	11	200mg	ethyl chloroformate	108.5mg	244.0mg
40	2-ethyl-3-methyl-4-vinyloxycarbonyloxy-5,6-difluoroquinoline	O-Vinyl	Et	F	H	F	17	30mg	vinyl chloroformate	16mg	25mg
41	2-ethyl-3-methyl-4-propargyloxycarbonyloxy-5,6-difluoroquinoline	O-Propargyl	Et	F	H	F	17	30mg	propargyl chloroformate	17mg	9mg
42	2-ethyl-3-methyl-4-chloromethyloxycarbonyloxy-5,6-difluoroquinoline	O-CH_2Cl	Et	F	H	F	17	30mg	chloromethyl chloroformate	18mg	4.8mg
43	2-ethyl-3-methyl-4-chloroacetyloxy-5,6-difluoroquinoline	CH_2Cl	Et	F	H	F	17	30mg	chloroacetyl chloride	16mg	11.3mg
45	2,3-dimethyl-4-ethyloxycarbonyloxy-5,6-difluoroquinoline	O-Et	Me	F	H	F	12	50mg	ethyl chloroformate	30mg	57.9mg
46	2,3-dimethyl-4-methanethiolcarbonyloxy-5,6-difluoro-quinoline	S-Me	Me	F	H	F	12	50mg	methyl chlorothioformate	30mg	33.1mg
47	2-ethyl-3-methyl-4-acryloyloxy-5,6-difluoroquinoline	Vinyl	Et	F	H	F	17	30mg	acryloyl chloride	14mg	27.5mg

48	2-ethyl-3-methyl-4-isobutyryloxy-5,6-difluoroquinoline	i-Bu	Et	F	H	F	17	30mg	isobutyryl chloride	15mg	31.2mg
49	2,3-dimethyl-4-(2-methyl-3,3-difluorocyclopropanecarbonyloxy) -5,6-difluoroquinoline		Me	F	H	F	12	30mg	2-methyl-3,3-difluoro-cyclopropanecarbonyl chloride	26mg	10.5mg
50	2,3-dimethyl-4-propargyloxycarbonyloxy-5,6-difluoroquinoline	O-Propargyl	Me	F	H	F	12	50mg	propargyl chloroformate	30mg	60mg
51	2,3-dimethyl-4-vinyloxycarbonyloxy-5,6-difluoroquinoline	O-Vinyl	Me	F	H	F	12	30mg	vinyl chloroformate	30mg	22.7mg
52	2,3-dimethyl-4-(3-butynyl)oxycarbonyloxy-5,6-difluoroquinoline	O-(3-Butynyl)	Me	F	H	F	12	50mg	3-butynyl chloroformate	50mg	32.7mg
55	2-ethyl-3-methyl-4-propanethiolcarbonyloxy-5,6-difluoroquinoline	S-Pr	Et	F	H	F	3	30mg	propyl chlorothioformate	50mg	15.1mg
56	2-ethyl-3-methyl-4-(3-butynyl)oxycarbonyloxy-5,6-difluoroquinoline	O-(3-Butynyl)	Et	F	H	F	3	50mg	3-butynyl chloroformate	50mg	58.4mg
57	2,3-dimethyl-4-allyloxycarbonyloxy-5,6-difluoroquinoline	O-Allyl	Me	F	H	F	12	50mg	allyl chloroformate	28.9mg	29.2mg
59	2,3-dimethyl-4-(4-pentynoyl)oxy-5,6-difluoroquinoline	3-Butynyl	Me	F	H	F	16	50mg	4-pentinic acid	23.5mg	46.9mg
60	2,3-dimethyl-4-(3,3,3-trifluoropropionyloxy)-5,6-difluoroquinoline	CH_2CF_3	Me	F	H	F	12	50mg	3,3,3-trifluoropropionic acid	30.7mg	40.4mg
62	2,3-dimethyl-4-methoxycarbonyloxy-5-trifluoromethyl-6-fluoroquinoline	O-Me	Me	CF3	H	F	14	100mg	methyl chloroformate	36.9mg	40.6mg
64	2,3-dimethyl-4-methoxycarbonyloxy-6-fluoro-7-trifluoromethyl-quinoline	O-Me	Me	H	CF3	F	14	100mg	methyl chloroformate	36.9mg	54.3mg
66	2,3-dimethyl-4-cyclopropanecarbonyloxy-5,6-dichloroquinoline	c-Pr	Me	Cl	H	Cl	15	200mg	cyclopropanecarbonyl chloride	86.7mg	75.2mg
67	2,3-dimethyl-4-methoxycarbonyloxy-5,6-dichloroquinoline	O-Me	Me	Cl	H	Cl	15	200mg	methyl chloroformate	78.4mg	110.1mg

69	2,3-dimethyl-4-cyclopropanecarbonyloxy-6,7-dichloroquinoline	c-Pr	Me	H	Cl	Cl	15	200mg	cyclopropanecarbonyl chloride	86.7mg	4mg
70	2,3-dimethyl-4-methoxycarbonyloxy-6,7-dichloroquinoline	O-Me	Me	H	Cl	Cl	15	200mg	methyl chloroformate	78.4mg	40.9mg
71	2-ethyl-3-methyl-4-cyclopropylethyloxycarbonyloxy-5,6-difluoroquinoline		Et	F	H	F	3	100mg	cyclopropylethyl chloroformate	80.2mg	133.6mg
72	2-ethyl-3-methyl-4-(3,3,3-trifluoropropyloxycarbonyloxy)- -5,6-difluoroquinoline		Et	F	H	F	3	100mg	3,3,3-trifluoropropyl chloroformate	95.3mg	81.2mg
73	~~2-ethyl-3-methyl-4-(3-pentyloxycarbonyloxy)-5,6-difluoroquinoline~~ 2-ethyl-3-methyl-4-(3-pentynyloxycarbonyloxy)-5,6-difluoroquinoline		Et	F	H	F	3	100mg	3-pentyl chloroformate	79.2mg	137.6mg
74	2,3-dimethyl-4-cyclopropylethyloxycarbonyloxy-5,6-difluoroquinoline		Me	F	H	F	4	200mg	cyclopropylethyl chloroformate	170.9mg	56.6mg
75	2,3-dimethyl-4-(3,3,3-trifluoropropyloxycarbonyloxy)-5,6-difluoroquinoline		Me	F	H	F	4	200mg	3,3,3-trifluoropropyl chloroformate	203mg	37.3mg
76	~~2,3-dimethyl-4-(3-pentyloxycarbonyloxy)-5,6-difluoroquinoline~~ 2,3-dimethyl-4-(3-pentynyloxycarbonyloxy)-5,6-difluoroquinoline		Me	F	H	F	4	200mg	3-pentyl chloroformate	168.6mg	62.6mg
77	2,3-dimethyl-4-cyclopropylethyloxycarbonyloxy-6,7-difluoroquinoline		Me	H	F	F	4	200mg	cyclopropylethyl chloroformate	170.9mg	230mg
78	2,3-dimethyl-4-(3,3,3-trifluoropropyloxycarbonyloxy)-6,7-difluoroquinoline		Me	H	F	F	4	200mg	3,3,3-trifluoropropyl chloroformate	203mg	212.1mg

79	~~2,3-dimethyl-4-(3-pentyloxycarbonyloxy)-6,7-difluoroquinoline~~ 2,3-dimethyl-4-(3-pentynyloxycarbonyloxy)-6,7-difluoroquinoline		Me	H	F	F	4	200mg	3-pentyl chloroformate	168.6mg	220.0mg
80	2-ethyl-3-methyl-4-(2-cyanoethyloxycarbonyloxy)-5,6-difluoro-quinoline		Et	F	H	F	3	100mg	2-cyanoethyl chloroformate	72.0mg	81.9mg
81	2,3-dimethyl-4-2-cyanoethyloxycarbonyloxy-5,6-difluoroquinoline		Me	F	H	F	4	200mg	2-cyanoethyl chloroformate	153.6mg	214mg